ATR12-351
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Netherton Syndrome
Conditions
Netherton Syndrome
Trial Timeline
Jun 19, 2024 → Aug 1, 2026
NCT ID
NCT06137157About ATR12-351
ATR12-351 is a phase 1 stage product being developed by Azitra for Netherton Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06137157. Target conditions include Netherton Syndrome.
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06137157 | Phase 1 | Recruiting |
Competing Products
8 competing products in Netherton Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-2325a | Daiichi Sankyo | Phase 1/2 | 24 |
| DS-2325a + DS-2325a + Placebo + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| DS-2325a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| Pimecrolimus 1% Cream | Novartis | Phase 1/2 | 32 |
| BCX17725 + Placebo | BioCryst Pharmaceuticals | Phase 1 | 30 |
| QRX003-2% Lotion + QRX003-4% Lotion QAM + Vehicle + QRX003-4% Lotion BID | Quoin Pharmaceuticals | Phase 2/3 | 32 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |